1-嘧啶-2-哌啶-4-醇 | 893755-98-1

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1-嘧啶-2-哌啶-4-醇
• 中文别名: 1-(2-嘧啶基)-4-哌啶醇
• 英文名称: 1-(pyrimidin-2-yl)piperidin-4-ol
• 英文别名: 1-pyrimidin-2-ylpiperidin-4-ol
• CAS: 893755-98-1
• 化学式: C₉H₁₃N₃O
• mdl: MFCD05864742
• 分子量: 179.222
• InChiKey: ZATIGSFNFLXZAS-UHFFFAOYSA-N

物化性质

• 沸点：
  365.5±52.0 °C(Predicted)
• 密度：
  1.234±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.555
• 拓扑面积：
  49.2
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Pyrimidin-2-yl-piperidin-4-ol
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Pyrimidin-2-yl-piperidin-4-ol
CAS number: 893755-98-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H13N3O
Molecular weight: 179.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-嘧啶-2-哌啶-4-醇 在 咪唑 、 tetrakis(actonitrile)copper(I) hexafluorophosphate 、 2-phenyl-2-(triethylsilyldioxy)propane 、 碘 、 三乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 17.0h， 生成 2-(4-phenylpiperidin-1-yl)pyrimidine
  参考文献：
  名称：

  结合卤素原子转移 (XAT) 和铜催化用于烷基碘和有机硼的模块化 Suzuki-Miyaura 型交叉偶联

  摘要：

  我们在这里报告了一种机制上不同的方法来实现烷基碘和芳基有机硼之间的 Suzuki-Miyaura 型交叉偶联。该过程需要铜催化剂，但与以前基于钯和镍系统的方法相比，它不使用金属来活化烷基亲电试剂。相反，该策略利用 α-氨基烷基自由基的卤素原子转移能力将仲烷基碘转化为相应的烷基自由基，然后与芳基、乙烯基、炔基、苄基和硼酸烯丙酯物质偶联。这些新颖的偶联反应具有简单的设置和条件（室温下 1 小时），并有助于获得制药行业所针对的特权基序。

  DOI：

  10.1021/jacs.1c12649
• 作为产物：
  描述：

  1-嘧啶-2-哌啶基-4-酮 在 sodium tetrahydroborate 、 水 作用下， 以 甲醇 、 乙酸乙酯 为溶剂， 反应 0.17h， 以100%的产率得到1-嘧啶-2-哌啶-4-醇
  参考文献：
  名称：

  WO2008/67121

  摘要：

  公开号：

文献信息

• PROTEIN KINASE INHIBITORS
  申请人：Sheppard S. George

  公开号：US20070203143A1

  公开（公告）日：2007-08-30

  Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.

  抑制蛋白激酶的化合物、含有这些化合物的组合物以及利用这些化合物治疗疾病的方法被披露。
• Multicyclic compounds and methods of their use
  申请人：Barbosa Joseph

  公开号：US20060258672A1

  公开（公告）日：2006-11-16

  This invention relates to multicyclic compounds, pharmaceutical compositions comprising them, and methods of their use in, for example, the treatment of cognitive disorders.

  这项发明涉及多环化合物，包括它们的药物组合物，以及它们在治疗认知障碍等方面的使用方法。
• Cobalt-Catalyzed Csp³–Csp³ Cross-Coupling of Functionalized Alkylzinc Reagents with Alkyl Iodides
  作者：Ferdinand H. Lutter、Lucie Grokenberger、Maximilian Benz、Paul Knochel

  DOI：10.1021/acs.orglett.0c00795

  日期：2020.4.17

  A mild cobalt-catalyzed Negishi-type cross-coupling of various functionalized dialkylzinc reagents with primary and secondary alkyl iodides in acetonitrile is reported using a combination of 20% CoCl2 and chelating nitrogen ligands. The method allows the construction of molecules with alkyl chains bearing sensitive functional groups at room temperature.

  据报道，结合使用20％CoCl 2和螯合氮配体，各种功能化二烷基锌试剂与伯烷基碘和仲烷基碘在钴中的温和钴催化Negishi型交叉偶联。该方法允许在室温下构建具有带有敏感官能团的烷基链的分子。
• NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS
  申请人：Son Jung Beom

  公开号：US20130274268A1

  公开（公告）日：2013-10-17

  The present invention relates to a bicyclic compound for modulating G protein-coupled receptors. The inventive compound provides preventing or treating a disease associated with the modulation of G protein-coupled receptors, particularly GPR119 G protein-coupled receptors.

  本发明涉及一种用于调节G蛋白偶联受体的双环化合物。该创新化合物可用于预防或治疗与调节G蛋白偶联受体相关的疾病，特别是GPR119 G蛋白偶联受体。
• [EN] NOVEL OXIME DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] NOUVEAUX DÉRIVÉS D'OXIMES ET LEUR UTILISATION COMME MODULATEURS ALLOSTÉRIQUES DE RÉCEPTEURS MÉTABOTROPIQUES DU GLUTAMATE
  申请人：DOMAIN THERAPEUTICS

  公开号：WO2011051478A1

  公开（公告）日：2011-05-05

  The present invention provides new oxime derivatives of the general formula (I), pharmaceutical compositions containing them and their use for the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. This invention further provides new oxime derivatives of the general formula (I) consisting of modulators of nervous system receptors sensitive to glutamate, which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders. In particular embodiments, the new oxime derivatives of the invention are modulators of metabotropic glutamate receptors (mGluRs). The invention further provides positive allosteric modulators of mGluRs and more specifically positive alSosteric modulators of mGiuR4.

  本发明提供了一般式（I）的新羟肟衍生物，包含它们的药物组合物以及它们用于治疗和/或预防与改变的谷氨酸信号和/或功能有关的疾病，和/或在哺乳动物中改变谷氨酸水平或信号会影响的疾病。本发明进一步提供了一般式（I）的新羟肟衍生物，它们是对谷氨酸敏感的神经系统受体的调节剂，因此特别适用于治疗和/或预防急性和慢性神经和/或精神障碍。在特定实施例中，本发明的新羟肟衍生物是代谢型谷氨酸受体（mGluRs）的调节剂。本发明还提供了mGluRs的正向变构调节剂，更具体地说是mGluR4的正向变构调节剂。